Trastuzumab binds HER2 on target cells and its Fc region engages Fcγ receptors on NK cells (and other effectors) to trigger antibody‑dependent cellular cytotoxicity (ADCC), killing HER2-expressing cells; complement-mediated cytotoxicity may also contribute.